Exploiting a rodent cell block for intrinsic resistance to HIV-1 gene expression in human T cells

mBio. 2023 Oct 31;14(5):e0042023. doi: 10.1128/mbio.00420-23. Epub 2023 Sep 7.

Abstract

Unlike humans, mice are unable to support HIV-1 infection. This is due, in part, to a constellation of defined minor, species-specific differences in conserved host proteins needed for viral gene expression. Here, we used precision CRISPR/Cas9 gene editing to engineer a "mousified" version of one such host protein, cyclin T1 (CCNT1), in human T cells. CCNT1 is essential for efficient HIV-1 transcription, making it an intriguing target for gene-based inactivation of virus replication. We show that isogenic cell lines engineered to encode CCNT1 bearing a single mouse-informed amino acid change (tyrosine in place of cysteine at position 261) exhibit potent, durable, and broad-spectrum resistance to HIV-1 and other pathogenic lentiviruses, and with no discernible impact on host cell biology. These results provide proof of concept for targeting CCNT1 in the context of one or more functional HIV-1 cure strategies.

Keywords: CCNT1; CRISPR/Cas9; CRM1; Cyclin T1; Rev; Tat; XPO1; genome engineering; human immunodeficiency virus; lentiviruses; nuclear export; transcription.

MeSH terms

  • Animals
  • Cell Line
  • Cyclin T / genetics
  • Cyclin T / metabolism
  • Gene Expression
  • HIV Infections*
  • HIV Seropositivity*
  • HIV-1* / physiology
  • Humans
  • Mice
  • Rodentia
  • T-Lymphocytes

Substances

  • Cyclin T